• Tomoki Origuchi, Kazuhiko Arima, Shin-Ya Kawashiri, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Toshiaki Tsukada, Toshiyuki Aramaki, Masako Furuyama, Taiichiro Miyashita, Yojiro Kawabe, Nozomi Iwanaga, Kaoru Terada, Yukitaka Ueki, Takaaki Fukuda, Katsumi Eguchi, and Atsushi Kawakami.
• Department of Rehabilitation Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8520, Japan. origuchi@nagasaki-u.ac.jp
• Mod Rheumatol. 2012 Aug 1; 22 (4): 584-8.

AbstractRecently, it was reported that remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a retrospective, multicenter study between October, 2003 and September, 2010, we investigated the characteristics of patients with paraneoplastic RS3PE syndrome who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the above criteria. Eight patients (seven men and one woman) developed cancer within 2 years of RS3PE syndrome onset. There was no significant difference between the neoplastic and nonneoplastic groups in the proportions of patients with fever, symmetrical polyarthritis, pitting edema, and good response to corticosteroids. Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the paraneoplastic RS3PE patients was significantly higher than that in patients without neoplasia (median 114.7 ng/ml) (p < 0.05). We found that high serum MMP-3 is characteristic of patients with paraneoplastic RS3PE syndrome.

30 keywords...

hide…